Pyxus shares have run up 100% over the past a few classes. On Monday, famed small-seller Citron Investigate warned against shorting Pyxus, and as an alternative named it a “speculative very long,” with “genuine administration” and a decent source of tradable shares. “The inventory could double from in this article prov

“We are tempering it, we have been meeting our commitments. And when We've got additional provide, which we will… We enables that for sale during the adult utilization industry. Take into account that the professional medical current market and the European market place can fetch us much more dough, whole cease,” he told analysts.